Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning DOI Open Access
Hiroyuki Suzuki, Yuki Okada, Tomohiro Tanaka

и другие.

Опубликована: Дек. 6, 2023

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular ATP into immunosuppressive adenosine with another CD73. The elevated in tumor microenvironment (TME) attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (mCD39) mAb, C39Mab-1 using Cell-Based Immunization Screening (CBIS) method. In this study, we determined critical flow cytometry. performed PA tag (12 amino acids)-substituted analysis (named scanning) RIEDL (5 determine By combination scanning scanning, identified conformational epitope, spanning three segments 275th 279th, 282nd 291st, 306th 323rd acids mCD39. These analyses would contribute identification membrane proteins.

Язык: Английский

Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer DOI Creative Commons

Kenichiro Ishikawa,

Hiroyuki Suzuki, Tomokazu Ohishi

и другие.

Oncology Reports, Год журнала: 2024, Номер 52(5)

Опубликована: Авг. 29, 2024

CD44 is a type I transmembrane glycoprotein associated with poor prognosis in various solid tumors. Since plays critical role tumor development by regulating cell adhesion, survival, proliferation and stemness, it has been considered target for therapy. Anti‑CD44 monoclonal antibodies (mAbs) have developed applied to antibody‑drug conjugates chimeric antigen receptor‑T Anti-pan‑CD44 mAbs, C44Mab‑5 C44Mab‑46, which recognize both standard (CD44s) variant isoforms were previously developed. The present study generated mouse IgG2a version of the anti‑pan‑CD44 mAbs (5‑mG2a C44Mab‑46‑mG2a) evaluate antitumor activities against CD44‑positive cells. Both 5‑mG2a C44Mab‑46‑mG2a recognized CD44s‑overexpressed CHO‑K1 (CHO/CD44s) cells esophageal line (KYSE770) flow cytometry. Furthermore, could activate effector presence CHO/CD44s exhibited complement-dependent cytotoxicity KYSE770 administration significantly suppressed xenograft compared control IgG2a. These results indicate that exert cancers be promising therapeutic regimen

Язык: Английский

Процитировано

6
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning DOI
Yuki Okada, Hiroyuki Suzuki, Tomohiro Tanaka

и другие.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Год журнала: 2024, Номер 43(2), С. 44 - 52

Опубликована: Март 20, 2024

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular adenosine triphosphate into immunosuppressive with another CD73. The elevated in tumor microenvironment attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (anti-mCD39) mAb, C

Язык: Английский

Процитировано

4
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas DOI Open Access

Kenichiro Ishikawa,

Hiroyuki Suzuki, Tomokazu Ohishi

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(17), С. 9190 - 9190

Опубликована: Авг. 24, 2024

CD44 regulates cell adhesion, proliferation, survival, and stemness has been considered a tumor therapy target. possesses the shortest standard (CD44s) variety of variant (CD44v) isoforms. Since expression CD44v is restricted in epithelial cells carcinomas compared to CD44s, promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C

Язык: Английский

Процитировано

3
Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C44Mab-108) Using Enzyme-Linked Immunosorbent Assay DOI
Hiroyuki Suzuki,

Mayuki Tawara,

Aoi Hirayama

и другие.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Год журнала: 2024, Номер 43(3), С. 85 - 89

Опубликована: Март 20, 2024

CD44 is a type I transmembrane glycoprotein and possesses various isoforms which are largely classified into standard (CD44s) variant (CD44v) isoforms. Some variant-encoded regions play critical roles in tumor progression. However, the function of 4 (CD44v4)-encoded region has not been fully understood. Using peptide immunization, we developed an anti-CD44v4 monoclonal antibody, C

Язык: Английский

Процитировано

0
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas DOI Open Access

Kenichiro Ishikawa,

Hiroyuki Suzuki, Tomokazu Ohishi

и другие.

Опубликована: Авг. 6, 2024

CD44 regulates cell adhesion, proliferation, survival, and stemness has been considered a tumor therapy target. possesses the shortest standard (CD44s) variety of variant (CD44v) isoforms. Since expression CD44v is restricted in epithelial cells carcinomas compared to CD44s, promising target for monoclonal antibody (mAb) therapy. We previously developed an anti‐CD44v10 mAb, C44Mab-18 (IgM, kappa) recognize exon 10-encoded region. In present study, mouse IgG2a version (C44Mab-18-mG2a) was generated evaluate antitumor activities against CD44-positive with established anti-pan C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity C44Mab-46-mG2a CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) oral squamous carcinoma lines (HSC-2 SAS) flow cytometry. exerted superior antibody‐dependent cellular cytotoxicity (ADCC) CD44v3–10. contrast, showed complement‐dependent (CDC) A similar tendency observed ADCC CDC HSC-2 SAS. Furthermore, administering or significantly suppressed CD44v3–10, HSC-2, SAS xenograft growth control IgG2a. These results indicate that could be therapeutic regimen CD44v10-positive tumors.

Язык: Английский

Процитировано

0
Oral Cancer: Prophylaxis, Etiopathogenesis and Treatment DOI Creative Commons
Violeta Popovici,

Emma Adriana Ozon

Current Issues in Molecular Biology, Год журнала: 2024, Номер 46(11), С. 12911 - 12913

Опубликована: Ноя. 13, 2024

Oral cancer contributes to approximately 3–10% of all mortality worldwide, and its incidence is continuously increasing due environmental conditions harmful habits the modern lifestyle [...]

Язык: Английский

Процитировано

0
Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C<sub>44</sub>Mab-108) using Enzyme-Linked Immunosorbent Assay DOI Open Access
Hiroyuki Suzuki,

Mayuki Tawara,

Aoi Hirayama

и другие.

Опубликована: Ноя. 3, 2023

CD44 is a type I transmembrane glycoprotein, and possesses various isoforms which are largely classified into standard variant (CD44v) isoforms. Some variant-encoded regions play critical roles in tumor progression. However, the function of 4 (CD44v4)-encoded region has not been fully understood. Using peptide immunization, we developed an anti-CD44v4 mAb, C44Mab-108, useful for flow cytometry, western blotting, immunohistochemistry. In this study, determined epitope C44Mab-108 by enzyme-linked immunosorbent assay (ELISA). We used alanine (or glycine)-substituted peptides CD44v4-encoded (amino acids 271-290 human CD44v3-10), found that did recognize alanine-substituted D280A W281A. Furthermore, these could inhibit recognition cytometry The results indicate binding includes Asp280 Trp281 CD44v3-10.

Язык: Английский

Процитировано

1
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning DOI Open Access
Hiroyuki Suzuki, Yuki Okada, Tomohiro Tanaka

и другие.

Опубликована: Дек. 6, 2023

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular ATP into immunosuppressive adenosine with another CD73. The elevated in tumor microenvironment (TME) attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (mCD39) mAb, C39Mab-1 using Cell-Based Immunization Screening (CBIS) method. In this study, we determined critical flow cytometry. performed PA tag (12 amino acids)-substituted analysis (named scanning) RIEDL (5 determine By combination scanning scanning, identified conformational epitope, spanning three segments 275th 279th, 282nd 291st, 306th 323rd acids mCD39. These analyses would contribute identification membrane proteins.

Язык: Английский

Процитировано

1